Natural Product Reports 2013-10-11

Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.

Jana Franke, Simone Eichner, Carsten Zeilinger, Andreas Kirschning

Index: Nat. Prod. Rep. 30(10) , 1299-323, (2013)

Full Text: HTML

Abstract

Covering 2005 to 2013. In this review recent progress in the development of heat shock proteins (Hsp90) in oncogenesis is illuminated. Particular emphasis is put on inhibitors such as geldanamycin and analogues that serve as a natural product show case. Hsp90 has emerged as an important target in cancer therapy and/or against pathogenic cells which elicit abnormal Hsp patterns. Competition for ATP by geldanamycin and related compounds abrogate the chaperone function of Hsp90. In this context, this account pursues three topics in detail: a) Hsp90 and its biochemistry, b) Hsp90 and its role in oncogenesis and c) strategies to create compound libraries of structurally complex inhibitors like geldanamycin on which SAR studies and the development of drugs that are currently in different stages of clinical testing rely.

Related Compounds

  • Geldanamycin

Related Articles:

The induction of heme oxygenase-1 suppresses heat shock protein 90 and the proliferation of human breast cancer cells through its byproduct carbon monoxide.

2014-01-01

[Toxicol. Appl. Pharmacol. 274(1) , 55-62, (2014)]

Bioreduction of aryl azides during mutasynthesis of new ansamitocins.

2013-09-06

[Org. Lett. 15(17) , 4442-5, (2013)]

Flotillin depletion affects ErbB protein levels in different human breast cancer cells.

2014-09-01

[Biochim. Biophys. Acta 1843(9) , 1987-96, (2014)]

Molecular dissection of the centrosome overduplication pathway in S-phase-arrested cells.

2009-04-01

[Mol. Cell. Biol. 29(7) , 1760-73, (2009)]

Role of heat shock proteins in oxygen radical-induced gastric apoptosis.

2015-01-01

[J. Surg. Res. 193(1) , 135-44, (2015)]

More Articles...